RecruitingNCT06939985

Cardiometabolic evalUation REgistry of Heart Failure

Cardiometabolic Risk Factors and Clinical Outcomes in Heart Failure: An Observational Cohort Study

Sponsor

Ruijin Hospital

Enrollment

5,000 participants

Start Date

Jan 1, 2015

Study Type

OBSERVATIONAL

Conditions

Heart Failure Metabolic Diseases Metabolic Cardiovascular Syndrome

Summary

This is a combined retrospective-prospective observational cohort study investigating the role of systemic and local cardiometabolic risk factors in cardiac structural/functional remodeling and clinical outcomes among heart failure (HF) patients. The study integrates retrospective clinical data (from the past 10 years) and prospective longitudinal follow-up (5 years) of HF patients across HF with reduced (HFrEF), mildly-reduced (HFmrEF), preserved (HFpEF) and improved ejection fraction (HFimpEF) phenotypes. Systemic metabolic factors (e.g., blood lipid profiles, glycemic levels, insulin resistance) and local factors (e.g., epicardial adipose tissue \[EAT\], perivascular adipose tissue \[PVAT\]) will be analyzed for their associations with changes in cardiac geometrics and function, dynamic transitions between HF phenotypes, as well as the occurrence of major adverse cardiovascular events (MACEs). The study seeks to advance risk stratification by integrated evaluation of cardiometabolic profiles so as to refine personalized cures in HF management.

Eligibility

Min Age: 18 Years

Inclusion Criteria6

Age ≥ 18 years
Chronic HF (NYHA II\~IV), including:
HFrEF (HF with reduced ejection fraction): ① HF symptoms±signs ; ② LVEF≤40%.
HFimpEF (HF with improved ejection fraction): ① HF symptoms±signs; ② previous LVEF ≤ 40% and a follow-up measurement of LVEF \>40%.
HFmrEF (HF with mildly reduced ejection fraction): ① HF symptoms±signs; ② LVEF 41%\~49%.
HFpEF (HF with preserved ejection fraction): ① HF symptoms±signs; ② LVEF ≥50%; ③ objective evidence of cardiac structural and/or functional abnormalities consistent with the presence of LV diastolic dysfunction/raised LV filling pressures, including raised natriuretic peptide.